Restrictions on pharmacist dispensing of mifepristone remain a hard pill to swallow

• DOI: 10.1002/jac5.2034
• Publication Date: 2024-10-22T06:19:08Z
• Authors: Kelli Boyden; Randy C. Hatton; Catherine M. Lynch; David B. Brushwood
• Keywords: Pill

Abstract This analysis explores the basis for US Food and Drug Administration (FDA) requiring a Risk Evaluation Mitigation Strategy (REMS) mifepristone termination of intrauterine pregnancy. Controversies surround its REMS. The safety efficacy are briefly reviewed with respect to FDA's actions. It is difficult justify continued requirement REMS by applying regulatory framework considering mifepristone's record. Drugs higher risks on market without an FDA‐mandated Canada removed all restrictions use abortion, which has not resulted in patient concerns. All pharmacists should be permitted dispense mifepristone. appears based more politics rather than evidence.